Edaravone (Radicava)

Approved by the FDA in 2017, based on a six-month clinical trial that showed that it reduced the decline in daily functioning associated with ALS. It is given intravenously for 10-14 days in a row once a month. It contains sodium bisulfite which should not be given to those with sulfite sensitivity. Side effects of the drug may include bruising, swelling, hives, gait disturbance, and shortness of breath.